NCT05098821Completed
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Pattern Recognition of Immune Cells in Atopic Dermatitis Patients Receiving Dupilumab
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25 (actual)
- First submitted
- 20 Oct 2021
- Start date
- 1 Oct 2019
- Primary completion date
- 8 Nov 2024
- Lead sponsor
- Charite University, Berlin, Germany
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05098821
What you commit to
- Study type: Observational
- Participants enrolled: 25
- From 1 Oct 2019 to the primary completion date, 8 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected allergy or reaction to any component of the dupilumab formulation
- Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of the severity of AD
Age
- Age below 18
Other
- Severe conjunctivitis or blepharitis
Who the study is looking for
- Age 18 and above
- Diagnosis of atopic dermatitis for ≥1 year
- Inadequate response to treatment with topical medications
- Confirmed dupilumab treatment
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin Coordinator of this site? Confirm its status | Berlin | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.